肺腺癌中PLK1的异常表达及其临床病理意义  

The abnormal expression and the clinicopathologic significance of Polo-like kinase 1(PLK1) in adenocarcinoma of the lung

作　　者：徐艳 沈小星 刘标 饶秋 时姗姗 王璇 何燕 黄培林[1] 

机构地区：[1]东南大学医学院病理与病理生理学系,江苏南京210009 [2]解放军杭州疗养院特勤疗养科,浙江杭州310007 [3]南京总医院病理科,江苏南京210002

出　　处：《东南大学学报（医学版）》2017年第5期804-810,共7页Journal of Southeast University(Medical Science Edition)

基　　金：江苏省普通高校研究生科研创新计划(CXZZ12_0120)

摘　　要：目的:探讨肺腺癌中PLK1的异常表达及临床病理意义。方法:免疫组化SP法检测266例I-IV期肺腺癌中PLK1的表达并分析其与临床病理特征、预后、TTF1和p53表达及分子学表型的关系。结果:PLK1过表达与吸烟(P<0.05)、转移/复发(P<0.01)及高临床分期(P<0.05)显著相关。常见于胶样腺癌(87.5%)、浸润性黏液腺癌(86.7%)和实体型腺癌(81.1%)(P<0.01)。在泌黏液型腺癌(73.1%)中发生率显著高于非泌黏液型腺癌(57.5%)(P<0.05)。PLK1过表达与KRAS突变、p53表达及三阴性肺腺癌显著相关(P<0.01),与TTF1表达、EGFR突变和EML4-ALK融合基因无显著相关性。肺腺癌中PLK1过表达与预后相关(P<0.01)且为独立预后因素(HR=2.235,P<0.01)。结论:PLK1过表达在部分肺腺癌的发病和进展过程中发挥重要作用。Objective： To explore the abnormal expression and the clinicopathologic significance of Polo-like kinase 1（PLK1） in adenocarcinoma（ADC） of the lung.Methods： The expressions of PLK1 in 266 patients with stage I-IV lung ADC were detected by immunohistochemistry（IHC）（SP method）.The correlations with PLK1 expression and the clinicopathological characteristics,the expression of TTF1 and p53 and the molecular phenotype were further analyzed.Results： There was a positive correlation with PLK1 overexprssion and smoking history（P 0.05）,metastesis/recurrence（P 0.01）,and higher stage（P 0.05）.PLK1 overexpression was more frequently found in colloid ADCs（87.5%）,invasive mucinous ADCs（86.7%） and solid ADCs（81.1%）（P 0.01）.PLK1 overexprssion was more common in mucin-product ADCs than in non mucin-product ADCs（P 0.05）.PLK1 overexpression was significiantly correlated with KRAS mutation（P 0.01）,p53 protein expression（P 0.01） and triple negative ADCs（P 0.01）,other than TTF1 expression,EGFR mutation or EML4-ALK fusion.In lung ADCs,PLK1 overexpression was strongly associated with prognosis（P 0.01）,and played as an independent prognostic role（HR = 2.235,P 0.01）.Conclusion： PLK1 overexpression possibly plays an important role in pathogenesis and evolution of a subset of lung ADCs.

关 键 词：肺腺癌 PLK1 表达 临床病理特征 KRAS突变 三阴性 预后 

分 类 号：R741.02[医药卫生—神经病学与精神病学]